Key cancer cell signal transduction pathways as therapeutic targets
- PMID: 16376541
- DOI: 10.1016/j.ejca.2005.07.034
Key cancer cell signal transduction pathways as therapeutic targets
Abstract
Growth factor signals are propagated from the cell surface, through the action of transmembrane receptors, to intracellular effectors that control critical functions in human cancer cells, such as differentiation, growth, angiogenesis, and inhibition of cell death and apoptosis. Several kinases are involved in transduction pathways via sequential signalling activation. These kinases include transmembrane receptor kinases (e.g., epidermal growth factor receptor EGFR); or cytoplasmic kinases (e.g., PI3 kinase). In cancer cells, these signalling pathways are often altered and results in a phenotype characterized by uncontrolled growth and increased capability to invade surrounding tissue. Therefore, these crucial transduction molecules represent attractive targets for cancer therapy. This review will summarize current knowledge of key signal transduction pathways, that are altered in cancer cells, as therapeutic targets for novel selective inhibitors. The most advanced targeted agents currently under development interfere with function and expression of several signalling molecules, including the EGFR family; the vascular endothelial growth factor and its receptors; and cytoplasmic kinases such as Ras, PI3K and mTOR.
Similar articles
-
New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors.Semin Oncol. 2006 Aug;33(4):407-20. doi: 10.1053/j.seminoncol.2006.04.005. Semin Oncol. 2006. PMID: 16890796 Review.
-
Antineoplastic effect of proliferation signal inhibitors: from biology to clinical application.J Nephrol. 2009 Jul-Aug;22(4):457-62. J Nephrol. 2009. PMID: 19662600 Review.
-
Intracellular signal transduction pathway proteins as targets for cancer therapy.J Clin Oncol. 2005 Aug 10;23(23):5386-403. doi: 10.1200/JCO.2005.23.648. Epub 2005 Jun 27. J Clin Oncol. 2005. PMID: 15983388 Review.
-
Targeting multiple signaling pathways as a strategy for managing prostate cancer: multifocal signal modulation therapy.Integr Cancer Ther. 2004 Dec;3(4):349-80. doi: 10.1177/1534735404270757. Integr Cancer Ther. 2004. PMID: 15523106 Review.
-
Rational bases for the development of EGFR inhibitors for cancer treatment.Int J Biochem Cell Biol. 2007;39(7-8):1416-31. doi: 10.1016/j.biocel.2007.05.008. Epub 2007 May 21. Int J Biochem Cell Biol. 2007. PMID: 17596994 Review.
Cited by
-
PIPKIγ regulates β-catenin transcriptional activity downstream of growth factor receptor signaling.Cancer Res. 2011 Feb 15;71(4):1282-91. doi: 10.1158/0008-5472.CAN-10-2480. Epub 2011 Feb 8. Cancer Res. 2011. PMID: 21303971 Free PMC article.
-
Targeted disruption of the galectin-3 gene results in decreased susceptibility to NNK-induced lung tumorigenesis: an oligonucleotide microarray study.J Cancer Res Clin Oncol. 2008 Jul;134(7):777-88. doi: 10.1007/s00432-007-0345-3. Epub 2008 Jan 17. J Cancer Res Clin Oncol. 2008. PMID: 18204863
-
DNA Damage Inducible Transcript 4 Gene: The Switch of the Metabolism as Potential Target in Cancer.Front Oncol. 2018 Apr 12;8:106. doi: 10.3389/fonc.2018.00106. eCollection 2018. Front Oncol. 2018. PMID: 29707520 Free PMC article. Review.
-
Structure-Guided Design of C4-alkyl-1,4-dihydro-2H-pyrimido[4,5-d][1,3]oxazin-2-ones as Potent and Mutant-Selective Epidermal Growth Factor Receptor (EGFR) L858R/T790M Inhibitors.Sci Rep. 2017 Jun 19;7(1):3830. doi: 10.1038/s41598-017-04184-9. Sci Rep. 2017. PMID: 28630494 Free PMC article.
-
Gene expression, regulation of DEN and HBx induced HCC mice models and comparisons of tumor, para-tumor and normal tissues.BMC Cancer. 2017 Dec 18;17(1):862. doi: 10.1186/s12885-017-3860-x. BMC Cancer. 2017. PMID: 29254483 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous
